Terms: = Leukemia AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Prognosis
372 results:
1. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
2. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Chan O; Al Ali N; Tashkandi H; Ellis A; Ball S; Grenet J; Hana C; Deutsch Y; Zhang L; Hussaini M; Song J; Yun S; Talati C; Kuykendall A; Padron E; Walker A; Roboz G; Desai P; Sallman D; Sweet K; Komrokji R; Lancet J
Blood Adv; 2024 Mar; 8(5):1075-1083. PubMed ID: 38170740
[TBL] [Abstract] [Full Text] [Related]
3. The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
Liao C; Nie J; Xu XJ; Zhang JY; Xu WQ; Song H; Shen HP; Shen DY; Zhao FY; Liang J; Miao J; Tang YM
Leuk Lymphoma; 2024 Jan; 65(1):91-99. PubMed ID: 37820046
[TBL] [Abstract] [Full Text] [Related]
4. Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors.
Tsai HK; Gogakos T; Lip V; Tsai JM; Li YD; Fisch AS; Weiss J; Yang W; Grimmett L; DiToro D; Schaefer EJ; Lindsley RC; Tran TH; Caron M; Langlois S; Sinnett D; Pikman Y; Nardi V; Kim AS; Silverman LB; Harris MH
J Mol Diagn; 2023 Sep; 25(9):665-681. PubMed ID: 37419244
[TBL] [Abstract] [Full Text] [Related]
5. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies.
Grasselli G; Calfee CS; Camporota L; Poole D; Amato MBP; Antonelli M; Arabi YM; Baroncelli F; Beitler JR; Bellani G; Bellingan G; Blackwood B; Bos LDJ; Brochard L; Brodie D; Burns KEA; Combes A; D'Arrigo S; De Backer D; Demoule A; Einav S; Fan E; Ferguson ND; Frat JP; Gattinoni L; Guérin C; Herridge MS; Hodgson C; Hough CL; Jaber S; Juffermans NP; Karagiannidis C; Kesecioglu J; Kwizera A; Laffey JG; Mancebo J; Matthay MA; McAuley DF; Mercat A; Meyer NJ; Moss M; Munshi L; Myatra SN; Ng Gong M; Papazian L; Patel BK; Pellegrini M; Perner A; Pesenti A; Piquilloud L; Qiu H; Ranieri MV; Riviello E; Slutsky AS; Stapleton RD; Summers C; Thompson TB; Valente Barbas CS; Villar J; Ware LB; Weiss B; Zampieri FG; Azoulay E; Cecconi M;
Intensive Care Med; 2023 Jul; 49(7):727-759. PubMed ID: 37326646
[TBL] [Abstract] [Full Text] [Related]
6. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
[TBL] [Abstract] [Full Text] [Related]
7. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A; Beylot-Barry M; Ram-Wolff C; Mear JB; Dalle S; d'Incan M; Ingen-Housz-Oro S; Orvain C; Abraham J; Dereure O; Charbonnier A; Cornillon J; Longvert C; Barete S; Boulinguez S; Wierzbicka-Hainaut E; Aubin F; Rubio MT; Bernard M; Schmidt-Tanguy A; Houot R; Pham-Ledard A; Michonneau D; Brice P; Labussière-Wallet H; Bouaziz JD; Grange F; Moins-Teisserenc H; Jondeau K; Michel L; Mourah S; Battistella M; Daguindau E; Loschi M; Picard A; Franck N; Maillard N; Huynh A; Nguyen S; Marçais A; Chaby G; Ceballos P; Le Corre Y; Maury S; Bay JO; Adamski H; Bachy E; Forcade E; Socié G; Bagot M; Chevret S; Peffault de Latour R; ; ;
Lancet; 2023 Jun; 401(10392):1941-1950. PubMed ID: 37105210
[TBL] [Abstract] [Full Text] [Related]
8. Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood
van Weelderen RE; Klein K; Harrison CJ; Jiang Y; Abrahamsson J; Arad-Cohen N; Bart-Delabesse E; Buldini B; De Moerloose B; Dworzak MN; Elitzur S; Fernández Navarro JM; Gerbing RB; Goemans BF; de Groot-Kruseman HA; Guest E; Ha SY; Hasle H; Kelaidi C; Lapillonne H; Leverger G; Locatelli F; Masetti R; Miyamura T; Norén-Nyström U; Polychronopoulou S; Rasche M; Rubnitz JE; Stary J; Tierens A; Tomizawa D; Zwaan CM; Kaspers GJL
J Clin Oncol; 2023 Jun; 41(16):2963-2974. PubMed ID: 36996387
[TBL] [Abstract] [Full Text] [Related]
9. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
[TBL] [Abstract] [Full Text] [Related]
10. Correlation of blood cell counts with mutant subtypes and impact prognosis in acute myeloid leukemia patients with FLT3 mutations.
Chen Y; Xie Y; Fang Y; Hong M; Shi J; Qian S
Hematology; 2023 Dec; 28(1):2172296. PubMed ID: 36738279
[TBL] [Abstract] [Full Text] [Related]
11. Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53.
Schandl CA; Mazzoni S; Znoyko I; Nahhas GJ; Chung D; Ding Y; Hess B; Wolff DJ
Cancer Genet; 2023 Apr; 272-273():23-28. PubMed ID: 36657266
[TBL] [Abstract] [Full Text] [Related]
12. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
Bader P; Rossig C; Hutter M; Ayuk FA; Baldus CD; Bücklein VL; Bonig H; Cario G; Einsele H; Holtick U; Koenecke C; Bakhtiar S; Künkele A; Meisel R; Müller F; Müller I; Penack O; Rettinger E; Sauer MG; Schlegel PG; Soerensen J; von Stackelberg A; Strahm B; Hauer J; Feuchtinger T; Jarisch A
Blood Adv; 2023 Jun; 7(11):2436-2448. PubMed ID: 36607834
[TBL] [Abstract] [Full Text] [Related]
13. Clinical impact of minimal residual disease and genetic subtypes on the prognosis of childhood acute lymphoblastic leukemia.
Yu CH; Jou ST; Su YH; Coustan-Smith E; Wu G; Cheng CN; Lu MY; Lin KH; Wu KH; Chen SH; Huang FL; Chang HH; Wang JL; Yen HJ; Li MJ; Chou SW; Ho WL; Liu YL; Chang CC; Lin ZS; Lin CY; Chen HY; Ni YL; Lin DT; Lin SW; Yang JJ; Ni YH; Pui CH; Yu SL; Yang YL
Cancer; 2023 Mar; 129(5):790-802. PubMed ID: 36537587
[TBL] [Abstract] [Full Text] [Related]
14. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Issa GC; Bidikian A; Venugopal S; Konopleva M; DiNardo CD; Kadia TM; Borthakur G; Jabbour E; Pemmaraju N; Yilmaz M; Short NJ; Maiti A; Sasaki K; Masarova L; Pierce S; Takahashi K; Tang G; Loghavi S; Patel K; Andreeff M; Bhalla K; Garcia-Manero G; Ravandi F; Kantarjian H; Daver N
Blood Adv; 2023 Mar; 7(6):933-942. PubMed ID: 36322818
[TBL] [Abstract] [Full Text] [Related]
15. Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia.
Kubota Y; Zawit M; Durrani J; Shen W; Bahaj W; Kewan T; Ponvilawan B; Mori M; Meggendorfer M; Gurnari C; LaFramboise T; Feurstein S; Sekeres MA; Visconte V; Godley LA; Haferlach T; Maciejewski JP
Leukemia; 2022 Dec; 36(12):2827-2834. PubMed ID: 36266327
[TBL] [Abstract] [Full Text] [Related]
16. Outcomes of Childhood Noninfant Acute Lymphoblastic leukemia With 11q23/
Attarbaschi A; Möricke A; Harrison CJ; Mann G; Baruchel A; De Moerloose B; Conter V; Devidas M; Elitzur S; Escherich G; Hunger SP; Horibe K; Manabe A; Loh ML; Pieters R; Schmiegelow K; Silverman LB; Stary J; Vora A; Pui CH; Schrappe M; Zimmermann M;
J Clin Oncol; 2023 Mar; 41(7):1404-1422. PubMed ID: 36256911
[TBL] [Abstract] [Full Text] [Related]
17. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
[TBL] [Abstract] [Full Text] [Related]
18. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia.
Shao J; Wang S; West-Szymanski D; Karpus J; Shah S; Ganguly S; Smith J; Zu Y; He C; Li Z
Sci Rep; 2022 Jul; 12(1):12410. PubMed ID: 35859008
[TBL] [Abstract] [Full Text] [Related]
19. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
[TBL] [Abstract] [Full Text] [Related]
20. Patient-specific comorbidities as prognostic variables for survival in myelofibrosis.
Sochacki AL; Bejan CA; Zhao S; Patel A; Kishtagari A; Spaulding TP; Silver AJ; Stockton SS; Pugh K; Dorand RD; Bhatta M; Strayer N; Zhang S; Snider CA; Stricker T; Nazha A; Bick AG; Xu Y; Savona MR
Blood Adv; 2023 Mar; 7(5):756-767. PubMed ID: 35420683
[TBL] [Abstract] [Full Text] [Related]
[Next]
